Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where David R. Karp is active.

Publication


Featured researches published by David R. Karp.


Immunity | 2001

Cr2, a candidate gene in the murine Sle1c lupus susceptibility locus, encodes a dysfunctional protein

Susan A. Boackle; V. Michael Holers; Xiaojiang S. Chen; Gerda Szakonyi; David R. Karp; Edward K. Wakeland; Laurence Morel

The major murine systemic lupus erythematosus (SLE) susceptibility locus, Sle1, corresponds to three loci independently affecting loss of tolerance to chromatin in the NZM2410 mouse. The congenic interval corresponding to Sle1c contains Cr2, which encodes complement receptors 1 and 2 (CR1/CR2, CD35/CD21). NZM2410/NZW Cr2 exhibits a single nucleotide polymorphism that introduces a novel glycosylation site, resulting in higher molecular weight proteins. This polymorphism, located in the C3d binding domain, reduces ligand binding and receptor-mediated cell signaling. Molecular modeling based on the recently solved CR2 structure in complex with C3d reveals that this glycosylation interferes with receptor dimerization. These data demonstrate a functionally significant phenotype for the NZM2410 Cr2 allele and strongly support its role as a lupus susceptibility gene.


Clinical and Experimental Immunology | 2006

Protein array autoantibody profiles for insights into systemic lupus erythematosus and incomplete lupus syndromes

Quan Zhen Li; Jinchun Zhou; Amy E. Wandstrat; Ferdicia Carr-Johnson; Valerie Klusas Branch; David R. Karp; Chandra Mohan; Edward K. Wakeland; Nancy J. Olsen

The objective of this study was to investigate the prevalence and clinical significance of a spectrum of autoantibodies in systemic lupus erythematosus and incomplete lupus syndromes using a proteome microarray bearing 70 autoantigens. Microarrays containing candidate autoantigens or control proteins were printed on 16‐section slides. These arrays were used to profile 93 serum samples from patients with systemic lupus erythematosus (SLE (n = 33), incomplete LE (ILE; n = 23), first‐degree relatives (FDRs) of SLE patients (n = 20) and non‐autoimmune controls (NC; n = 17). Data were analysed using the significance analysis of microarray (SAM) and clustering algorithms. Correlations with disease features were determined. Serum from ILE and SLE patients contained high levels of IgG autoantibodies to 50 autoantigens and IgM autoantibodies to 12 autoantigens. Elevated levels of at least one IgG autoantibody were detected in 26% of SLE and 19% of ILE samples; elevated IgM autoantibodies were present in 13% of SLE and 17% of ILE samples. IgG autoantibodies segregated into seven clusters including two specific for DNA and RNA autoantigens that were correlated with the number of lupus criteria. Three IgG autoantibody clusters specific for collagens, DNA and histones, were correlated with renal involvement. Of the four IgM autoantibody clusters, two were correlated negatively with the number of lupus criteria; none were correlated with renal disease. The IgG : IgM autoantibody ratios generally showed a stepwise increase in the groups following disease burden from NC to SLE. Insights derived from the expanded autoantibody profiling made possible with the antigen array suggest differences in autoreactivity in ILE and SLE. Determining whether the IgM aurotreactivity that predominates in ILE represents an early stage prior to IgG switching or is persistent and relatively protective will require further longitudinal studies.


Immunity | 2002

Complement Receptors CD21/35 Link Innate and Protective Immunity during Streptococcus pneumoniae Infection by Regulating IgG3 Antibody Responses

Karen M. Haas; Minoru Hasegawa; Douglas A. Steeber; Jonathan C. Poe; Mark D. Zabel; Cheryl B. Bock; David R. Karp; David E. Briles; John H. Weis; Thomas F. Tedder

The CD21/35 receptor provides an important link between innate and adaptive immunity. Its importance during protective immune responses to encapsulated extracellular bacteria was assessed using a new line of mice completely deficient in CD21/35 expression (CD21/35(-/-)). CD21/35 expression was essential for the rapid trapping of C3dg-antigen complexes by B cells in vivo, especially in splenic marginal zones. Despite normal B cell development in CD21/35(-/-) mice, T cell-independent and -dependent antibody responses to low-dose antigens were significantly decreased, with a striking impairment in IgG3 responses. Accordingly, CD21/35(-/-) mice were more susceptible to acute lethal Streptococcus pneumoniae infection. Thus, CD21/35 expression is critical for early protective antibody responses to lethal pathogens that rapidly multiply and quickly overwhelm the immune system.


Journal of Experimental Medicine | 2003

A New Type of Metal Recognition by Human T Cells: Contact Residues for Peptide-independent Bridging of T Cell Receptor and Major Histocompatibility Complex by Nickel

Katharina Gamerdinger; Corinne Moulon; David R. Karp; Jeroen van Bergen; Frits Koning; Doris Wild; Ulrike Pflugfelder; Hans Ulrich Weltzien

In spite of high frequencies of metal allergies, the structural basis for major histocompatibility complex (MHC)-restricted metal recognition is among the unanswered questions in the field of T cell activation. For the human T cell clone SE9, we have identified potential Ni contact sites in the T cell receptor (TCR) and the restricting human histocompatibility leukocyte antigen (HLA)-DR structure. The specificity of this HLA-DR–promiscuous VA22/VB17+ TCR is primarily harbored in its α chain. Ni reactivity is neither dependent on protein processing in antigen-presenting cells nor affected by the nature of HLA-DR–associated peptides. However, SE9 activation by Ni crucially depends on Tyr29 in CDR1α, an N-nucleotide–encoded Tyr94 in CDR3α, and a conserved His81 in the HLA-DR β chain. These data indicate that labile, nonactivating complexes between the SE9 TCR and most HLA-DR/peptide conjugates might supply sterically optimized coordination sites for Ni ions, three of which were identified in this study. In such complexes Ni may effectively bridge the TCR α chain to His81 of most DR molecules. Thus, in analogy to superantigens, Ni may directly link TCR and MHC in a peptide-independent manner. However, unlike superantigens, Ni requires idiotypic, i.e., CDR3α-determined TCR amino acids. This new type of TCR–MHC linkage might explain the high frequency of Ni-reactive T cells in the human population.


Arthritis & Rheumatism | 2014

Treatment of Lupus Nephritis with Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study

Anca Askanase; Margie Byron; Lynette Keyes-Elstein; Patricia Cagnoli; W. Joseph McCune; W. Winn Chatham; Gabriel Contreras; David I. Daikh; Maria Dall'Era; David Wofsy; Anne Davidson; Betty Diamond; Meggan Mackay; Linna Ding; Wendy Gao; Mary Anne Dooley; Hilda Fragoso-Loyo; Jorge Sanchez-Guerrero; David R. Karp; Nancy J. Olsen; Meenakshi Jolly; Kenneth C. Kalunian; Diane L. Kamen; Iris Lee; Marc C. Levesque; S. Sam Lim; Cesar Ramos-Remus; Brad H. Rovin; Peter Sayre; Dawn Smilek

To assess the efficacy and safety of a 24‐week course of abatacept in the treatment of active lupus nephritis and to assess the potential of abatacept to induce “clinical tolerance,” defined as sustained clinical quiescence of lupus nephritis after discontinuation of immunosuppressive therapy.


Genes and Immunity | 2008

Interferon regulatory factor-5 is genetically associated with systemic lupus erythematosus in African Americans

Jennifer A. Kelly; J. M. Kelley; Kenneth M. Kaufman; J. Kilpatrick; Gail R. Bruner; Joan T. Merrill; Judith A. James; Summer G Frank; E. Reams; Elizabeth E. Brown; A. W. Gibson; Miranda C. Marion; Carl D. Langefeld; Quan Zhen Li; David R. Karp; Edward K. Wakeland; Michelle Petri; Rosalind Ramsey-Goldman; John D. Reveille; Luis M. Vilá; Graciela S. Alarcón; Robert P. Kimberly; John B. Harley; Jeffrey C. Edberg

Increased expression of interferon (IFN)-inducible genes is implicated in the pathogenesis of systemic lupus erythematosus (SLE). One transcription factor responsible for regulating IFN, interferon regulatory factor-5 (IRF5), has been associated with SLE in genetic studies of Asian, Caucasian and Hispanic populations. We genotyped up to seven polymorphic loci in or near IRF5 in a total of 4870 African-American and Caucasian subjects (1829 SLE sporadic cases and 3041 controls) from two independent studies. Population-based case–control comparisons were performed using the Pearsons χ2-test statistics and haplotypes were inferred using HaploView. We observed significant novel associations with the IRF5 variants rs2004640 and rs3807306 in African Americans and replicated previously reported associations in Caucasians. While we identified risk haplotypes, the majority of haplotypic effects were accounted for by one SNP (rs3807306) in conditional analyses. We conclude that genetic variants of IRF5 associate with SLE in multiple populations, providing evidence that IRF5 is likely to be a crucial component in SLE pathogenesis among multiple ethnic groups.


Circulation Research | 2005

FcγRIIB Mediates C-Reactive Protein Inhibition of Endothelial NO Synthase

Chieko Mineo; Andrew K. Gormley; Ivan S. Yuhanna; Sherri Osborne-Lawrence; Linda L. Gibson; Lisa Hahner; Ralph V. Shohet; Steven Black; Jane E. Salmon; David Samols; David R. Karp; Gail D. Thomas; Philip W. Shaul

C-reactive protein (CRP) is an acute-phase reactant that is positively correlated with cardiovascular disease risk and endothelial dysfunction. Whether CRP has direct actions on endothelium and the mechanisms underlying such actions are unknown. Here we show in cultured endothelium that CRP prevents endothelial NO synthase (eNOS) activation by diverse agonists, resulting in the promotion of monocyte adhesion. CRP antagonism of eNOS occurs nongenomically and is attributable to blunted eNOS phosphorylation at Ser1179. Okadaic acid or knockdown of PP2A by short-interference RNA reverses CRP antagonism of eNOS, indicating a key role for the phosphatase. Aggregated IgG, the known ligand for Fc&ggr; receptors, causes parallel okadaic acid–sensitive loss of eNOS function, Fc&ggr;RIIB expression is demonstrable in endothelium, and heterologous expression studies reveal that CRP antagonism of eNOS requires Fc&ggr;RIIB. In Fc&ggr;RIIB+/+ mice, CRP blunts acetylcholine-induced increases in carotid artery vascular conductance; in contrast, CRP enhances acetylcholine responses in Fc&ggr;RIIB−/− mice. Thus Fc&ggr;RIIB mediates CRP inhibition of eNOS via PP2A, providing a mechanistic link between CRP and endothelial dysfunction.


Journal of Immunology | 2006

Oxidative Stress Promotes Polarization of Human T Cell Differentiation Toward a T Helper 2 Phenotype

Miranda R. King; Anisa S. Ismail; Laurie S. Davis; David R. Karp

These studies were conducted to determine the effects of oxidative stress on human T cell differentiation and polarization into Th1 or Th2 phenotypes. Highly purified naive CD4+ T cells were isolated from PBMC of healthy, nonatopic donors. CD4+ T cells were stimulated with anti-CD3 and anti-CD28 mAb in the presence or absence of oxidative stress as supplied by 2,3-dimethoxy-1,4-naphthoquinone (DMNQ), which generates a low level of superoxide anion. Increases in cellular superoxide were observed by exposure to DMNQ. Exposure of unpolarized CD4+ T cells to IL-12 or IL-4 resulted in a Th1 or Th2 phenotype, respectively. T cells stimulated in the absence of polarizing cytokines secreted modest amounts of IFN-γ and TNF-α. Cells stimulated in the continuous presence of 5 μM DMNQ, displayed a marked up-regulation in Th2 cytokines, including IL-4, IL-5, and IL-13, but not the Th1 cytokine IFN-γ. Th2 responses were blunted by concomitant exposure to thiol antioxidants. Long-term exposure of T cells to DMNQ resulted in growth of cells expressing CCR4, and a decrease in cells expressing CXCR3, indicating phenotypic conversion to Th2 cells. These results suggest that oxidative stress favors a Th2-polarizing condition.


Cancer | 1976

The value of serial measurement of both human chorionic gonadotropin and alpha-fetoprotein for monitoring germinal cell tumors

Elliott Perlin; James E. Engeler; Mitchell Edson; David R. Karp; K. Robert McIntire; Thomas A. Waldmann

Quantitative serial serum measurements of human chorionic gonadotropin (hCG) and alpha‐fetoprotein (AFP) levels using sensitive double‐antibody radio‐immunoassays were performed in nine patients with germinal cell tumors before and during treatment. The sera of eight of the nine were found to have a hCG marker and five of the nine an AFP marker. The sera of four patients were found to have both. Serial serum levels of hCG, of AFP, or both were useful for monitoring disease activity during therapy in all nine patients. In two patients tumor masses failed to diminish during chemotherapy, but the tumor markers fell appropriately. At surgery one patient had a mature teratoma, the other a mature teratoma with a microscopic focus of an embryonal cell tumor. In one patient tumor reactivation was reflected by the emergence of only one of two previously elevated tumor markers. One patient had a rise in hCG, another a rise in both markers coincident with recurrence of tumor. Serial measurements of AFP and hCG are useful for following the response to therapy of germinal tumors, and can assist in making therapeutic decisions.


Arthritis Research & Therapy | 2011

Risk factors for ANA positivity in healthy persons

Quan Zhen Li; David R. Karp; Jiexia Quan; Valerie Klusas Branch; Jinchun Zhou; Yun Lian; Benjamin F. Chong; Edward K. Wakeland; Nancy J. Olsen

IntroductionThe finding of antinuclear antibody (ANA) positivity in a healthy individual is usually of unknown significance and in most cases is benign. However, a subset of such individuals is at risk for development of autoimmune disease. We examined demographic and immunological features that are associated with ANA positivity in clinically healthy persons to develop insights into when this marker carries risk of progression to lupus.MethodsBiological samples from healthy individuals and patients with systemic lupus erythematosus (SLE) were obtained from the Dallas Regional Autoimmune Disease Registry (DRADR). Measurements carried out on serum samples included ANA, extractable nuclear antibodies (ENA) and autoantibody profiling using an array with more than 100 specificities. Whole blood RNA samples from a subset of individuals were used to analyze gene expression on the Illumina platform. Data were analyzed for associations of high ANA levels with demographic features, the presence of other autoantibodies and with gene expression profiles.ResultsOverall, ANA levels are significantly higher in females than in males and this association holds in patients with the autoimmune diseases lupus and rheumatoid arthritis (RA) as well as in healthy controls (HC). Age was not significantly associated with ANA levels and the elevated ANA values could not be explained by higher IgG levels. Another autoantibody, anti- cyclic citrullinated peptide (CCP), did not show gender dimorphism in rheumatoid arthritis (RA) or healthy individuals. The autoantigen array showed significant elevations of other autoantibodies in high ANA HCs. Some of these autoantibodies were directed to antigens in skin and others were related to autoimmune conditions of kidney, thyroid or joints. Gene expression analyses showed a greater prevalence of significantly upregulated genes in HCs with negative ANA values than in those with significant ANA positivity. Genes upregulated in high ANA HCs included a celiac disease autoantigen and some components of the Type I interferon (IFN) gene signature.ConclusionsRisks for ANA positivity include female gender and organ-specific autoimmunity. Upregulation of skin-specific autoantibodies may indicate that early events in the break of tolerance take place in cutaneous structures. Some of these changes may be mediated by Type I IFN. Blood profiling for expressed autoantibodies and genes has the potential to identify individuals at risk for development of autoimmune diseases including lupus.

Collaboration


Dive into the David R. Karp's collaboration.

Top Co-Authors

Avatar

Nancy J. Olsen

Pennsylvania State University

View shared research outputs
Top Co-Authors

Avatar

Judith A. James

University of Oklahoma Health Sciences Center

View shared research outputs
Top Co-Authors

Avatar

Quan Zhen Li

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Edward K. Wakeland

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Joel M. Guthridge

Oklahoma Medical Research Foundation

View shared research outputs
Top Co-Authors

Avatar

Nishanth Marthandan

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Paula A. Guidry

University of Texas Southwestern Medical Center

View shared research outputs
Top Co-Authors

Avatar

Glenys Thomson

University of California

View shared research outputs
Top Co-Authors

Avatar

John B. Harley

Cincinnati Children's Hospital Medical Center

View shared research outputs
Researchain Logo
Decentralizing Knowledge